Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel
- 454 Downloads
The prevalence of HCV infection is higher among prisoners than in the general population. The introduction of HCV direct-acting antivirals (DAA) holds the potential to improve clinical outcomes also in inmates. However, treatment of hepatitis C in inmates has to face several clinical and logistical issues which are peculiar of prison environment. Recommendations on the management of HCV infection specific for the penitentiary setting in the DAA era remain scant. The Italian Society for Penitentiary Medicine and Healthcare has, therefore, issued these recommendations, to provide clinicians with a guide for the comprehensive management of HCV infection in the restriction setting, taking into account its peculiar characteristics.
Dedicated diagnostic and treatment procedures should be established in each prison. In particular, the use of DAAs appears crucial to provide patients with an effective therapeutic option, able to overcome the limitations of IFN-based regimens with a short period of treatment. DAA treatment should be initiated as soon as possible in all eligible subjects with the aim to cure the patient, as well as to limit the transmission of HCV infection both inside the penitentiary system and to the free community, once the inmates ends his/her release. Importantly, efforts should be made to open a discussion with regulatory bodies, to define specific regulations aimed to guarantee wide access to effective therapies of all eligible patients, to optimize the management of and the adherence to the HCV treatment, and to ensure the therapeutic continuity after discharge from prison.
KeywordsDAA HCV Infection Penitentiary medicine Management
Editorial assistance for the preparation of this manuscript was provided by Luca Giacomelli, PhD; this assistance was supported by an unrestricted grant by Abbvie.
Compliance with ethical standards
Conflict of interest
- 1.United Nations. 45/111 Basic principles for the treatment of prisoners, 1990. http://www.un.org/documents/ga/res/45/a45r111.htm. Accessed 10 Jan 2015.
- 2.Dublin declaration on HIV/AIDS in prisons in Europe and central Asia, 2004. http://16889-presscdn-0-48.pagely.netdna-cdn.com/wp-content/uploads/2013/06/rep-2004-dublin-declaration-en.pdf. Accessed 29 July 2016.
- 6.Thematic report: prisoners monitoring implementation of the dublin d claration on partnership to fight HIV/AIDS in Europe and Central Asia: 2012 Progress, 2013. http://ecdc.europa.eu/en/publications/Publications/dublin-declaration-monitoring-report-prisoners-october-2013.pdf. Accessed 29 July 2016.
- 7.Dolan K, Wirtz AL, Moazen B, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016. doi: 10.1016/S0140-6736(16)30466-4 (Epub ahead of print).
- 10.Jurgens R. 2009-WHO Technical paper. Geneva, pp. 13–72.Google Scholar
- 11.Neff MJ, CDC. CDC updates guidelines for prevention and control of infections with hepatitis viruses in correctional settings. Am Fam Physician. 2003;67:2620, 2622, 2625.Google Scholar
- 14.Department US, of Justice. Key facts at a glance. Correctional populations, 1980–2000. 2003.Google Scholar
- 21.Italian Ministry of Justice, 2014. https://www.giustizia.it/giustizia/it/mg_1_14_1.wp?facetNode_1=1_5_31&facetNode_4=0_2_10_1&facetNode_3=0_2_10&facetNode_2=0_2&previsiousPage=mg_1_14&contentId=SST613888. Accessed 20 Aug 2016.
- 24.http://www.epatitec.info/default.asp?id=743. Accessed 30 Oct 2016.
- 31.Semaille C, Le Strat Y, Chiron E, Prevacar Group, et al. Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy. Euro Surveill. 2013;18.Google Scholar
- 34.Foschi A, Casana M, Radice A, et al. CORRESPONDENCE: Hepatitis C management in prisons: An insight into daily clinical practice in three major Italian Correctional Houses. Hepatology. 2016. doi: 10.1002/hep.28609 (Epub ahead of print).
- 35.Aspinall EJ, Mitchell W, Schofield J, et al. A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. J Viral Hepat. 2016;23:1009–1016.Google Scholar
- 38.The alcohol use disorders identification test guidelines for use in primary care, 2001. http://www.talkingalcohol.com/files/pdfs/WHO_audit.pdf. Accessed 30 Oct 2016.
- 39.Starnini ICAR 2016.Google Scholar
- 43.Agenzia Italiana del Farmaco, 2016. http://www.agenziafarmaco.gov.it/it/content/algoritmi-terapeutici. Accessed 20 Aug 2016.
- 44.Martin NK, Hickman M, Miners A, et al. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open. 2013;3:e003153.Google Scholar
- 47.Darke J, Cresswell T, McPherson S, Hamoodi A. Hepatitis C in a prison in the North East of England: what is the economic impact of the universal offer of testing and emergent medications? J Public Health (Oxf). 2015 (Epub ahead of print).Google Scholar